Top Page
Prophase Labs
(NASDAQ:PRPH)
Prophase Labs (PRPH) vs. SPDR S&P 500 ETF (SPY)
Prophase Labs Business Overview & Revenue Model
Prophase Labs Earnings Call Summary
Prophase Labs Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.34M | 6.77M | 44.38M | 122.65M | 79.04M | 14.51M |
| Gross Profit | 2.02M | -150.00K | 16.24M | 70.65M | 32.81M | 4.61M |
| EBITDA | -26.18M | -32.34M | -14.83M | 28.73M | 11.39M | -1.49M |
| Net Income | -41.45M | -53.36M | -16.78M | 18.46M | 6.27M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 42.04M | 63.20M | 91.93M | 87.65M | 89.30M | 31.41M |
| Cash, Cash Equivalents and Short-Term Investments | 171.00K | 678.00K | 4.74M | 17.44M | 17.26M | 8.46M |
| Total Debt | 5.54M | 24.57M | 21.38M | 6.96M | 14.90M | 14.72M |
| Total Liabilities | 30.61M | 55.85M | 42.54M | 24.02M | 30.67M | 20.85M |
| Stockholders Equity | 11.44M | 7.35M | 49.38M | 63.63M | 58.63M | 10.56M |
Cash Flow | ||||||
| Free Cash Flow | -6.03M | -18.44M | -14.50M | 24.63M | -17.85M | -4.28M |
| Operating Cash Flow | -6.09M | -17.54M | -11.35M | 28.55M | -13.62M | -2.59M |
| Investing Cash Flow | 783.00K | 2.42M | -1.37M | -2.08M | -19.67M | -1.02M |
| Financing Cash Flow | 8.79M | 14.19M | 5.76M | -26.02M | 35.13M | 9.99M |
Prophase Labs Technical Analysis
Prophase Labs Risk Analysis
Prophase Labs Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $23.28M | ― | -58.30% | ― | ― | ― | |
51 Neutral | $7.44B | -0.20 | -46.00% | 2.27% | 22.80% | -2.27% | |
50 Neutral | $9.43M | ― | -531.54% | ― | 11.20% | 63.16% | |
47 Neutral | $14.71M | ― | -58.71% | ― | -79.66% | -141.87% | |
47 Neutral | $12.79M | ― | -1.98% | ― | 156.93% | 92.75% | |
41 Neutral | $8.81M | ― | -106.83% | ― | -95.85% | 49.94% | |
| ― | $275.14M | ― | -58.27% | ― | ― | ― |
Prophase Labs Corporate Events
ProPhase Labs reported significant financial and operational improvements for the first half of 2025, including a strengthened equity position and reduced liabilities. The company achieved a key U.S. patent for its BE-Smart™ Esophageal Adenocarcinoma Risk Assessment test, positioning it for faster market entry. Additionally, ProPhase streamlined its operations, reduced costs, and improved margins, setting a path for future growth. The company is also exploring a strategic treasury initiative involving digital assets to complement its core businesses.
ProPhase Labs, Inc. announced the resignation of its Chief Operating Officer, Stu Hollenshead, effective July 31, 2025, who will transition to a marketing consultant role. The company is searching for a successor, with interim duties managed by the executive team. Additionally, ProPhase Labs appointed Steven M. Plumb as its fractional Chief Financial Officer on August 6, 2025. Plumb, a seasoned financial executive, will provide operational advice and oversee SEC filings, while CEO Ted Karkus remains the principal financial officer.
On July 29, 2025, ProPhase Labs announced the filing of a Preliminary Proxy Statement with the SEC, aiming to increase authorized shares to 1 billion. This strategic move is intended to attract high-value transactions and industry-leading participants in the crypto treasury space, enhancing the company’s growth potential and flexibility. The Board of Directors has recommended shareholders vote in favor of these proposals at the Special Meeting on August 29, 2025, to strengthen ProPhase Labs’ ability to innovate and create shareholder value.
On July 22, 2025, ProPhase Labs entered into a Securities Purchase Agreement with two investors for a private placement of senior secured convertible notes and warrants, amounting to a principal cash investment of $3,000,000. The transaction is designed to protect long-term shareholder value by preventing excessive dilution and downward price spirals, while also granting investors a first priority security interest in the company’s assets. The net proceeds will be used for working capital, general corporate purposes, and debt repayment. The agreement includes provisions to ensure the company retains control over its assets unless a default occurs.
On July 18, 2025, ProPhase Labs, Inc. held its Annual Meeting of Stockholders where several key decisions were made. The company’s stockholders elected board members, ratified the appointment of independent auditors, approved executive compensation, and decided on the frequency of future advisory votes on executive compensation. Notably, Ms. Carolina Abenante was appointed to the Audit Committee, leading to the company’s compliance with Nasdaq Listing Rules.
On July 23, 2025, ProPhase Labs announced the closing of a $3 million private placement financing with two investors involving senior secured convertible notes and warrants to purchase common stock. The funds will be used for working capital, corporate purposes, and debt repayment, while supporting potential liquidity events and crypto strategies.
On July 18, 2025, ProPhase Labs’ Board of Directors authorized the exploration of a potential reverse merger with a digital asset-focused company to enhance shareholder value and market positioning. This strategic initiative includes a crypto treasury strategy and aims to identify growth opportunities at the intersection of life sciences and financial innovation, although no binding agreement has been made yet.
ProPhase Labs, Inc. resolved a compliance issue with Nasdaq’s audit committee requirements after a vacancy was created by the resignation of Eleanor McBrier. The company appointed Carolina Abenante to the Board and Audit Committee, regaining compliance with Nasdaq rules as confirmed by Nasdaq on June 25, 2025.
On June 22, 2025, ProPhase Labs entered into two identical loan agreements totaling $500,000 each with its CEO, Ted Karkus, and an unaffiliated investor. The loans, which include a 20% original issue discount and a 10% annual interest rate, are secured by the company but subordinate to other lenders up to $6 million. Additionally, the company issued 500,000 unvested warrants for common stock, contingent on future shareholder approval. This move, approved by the Audit Committee, reflects ProPhase Labs’ strategic financial maneuvering to bolster its capital structure.
On June 26, 2025, ProPhase Labs announced that it received a 180-day extension from Nasdaq to meet the minimum bid price requirement of $1.00 per share, following an initial period ending on June 24, 2025. This extension allows the company until December 22, 2025, to regain compliance, failing which its stock may face delisting. The company is actively monitoring its stock price and exploring options to meet the requirement, although there is no assurance of compliance within the extended period. This development does not impact ProPhase Labs’ business operations or reporting obligations.
On June 20, 2025, ProPhase Labs, Inc. appointed Carolina Abenante as an independent director to fill a vacancy on its Board of Directors. She was also appointed to the Nominating and Corporate Governance Committee and as Chair of the Compensation Committee, with her term set to expire at the 2025 annual meeting of stockholders. The Board intends to nominate her for re-election and plans to appoint her to the Audit Committee following the annual meeting. Ms. Abenante meets the independence and financial literacy requirements set by Nasdaq and the SEC.